See other companies on Welcome to the Jungle
Healx
Drug discovery for rare diseases
- 101-200 employees
- Healthcare
- B2B
- Artificial Intelligence
- MedTech
- Cambridge, UK
Jump to section
Company mission
Healx's mission is to pioneer the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world.
58% employee growth in 12 months
Our take
There are 7,000 known rare diseases around the world, and only 5% of them have an approved treatment. Healx solves this problem by leveraging AI to develop and identify drug treatments for rare conditions.
Healx's platform, Healnet, uses machine learning to find connections between rare diseases and existing drugs. Repurposing drugs is more time and cost effective than developing new treatments, and therefore has broad appeal within the pharma community.
At the moment, the company is focused on rare conditions such as Fragile X syndrome, but they are looking to rapidly expand their scope to other diseases.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Enhanced parental leave
- Generous pension contributions
- Share options
- Remote and flexible working
- Quarterly socials
- Private medical insurance
- Life insurance
Company values
- Care for rare: Rare disease patients are at the heart of everything we do.
- Grow as individuals: We are learners, always looking to extend and enhance our expertise.
- Win as a team: We are united in our mission to help patients.
- Innovate and deliver: The road ahead is challenging.
Funding (last 2 of 5 rounds)
Aug 2024
$47m
SERIES C
Nov 2023
$22m
LATE VC
Total funding: $136.9m
This company has top investors
Leadership
Dr Tim Guilliams
(CEO)Previously worked as a Junior Associate Fellow at the Centre for Science and Policy. Is Founding Director and Trustee of Cambridge Rare Disease Network, and an Entrepreneurship Fellow at Cambridge Judge Business School.
David Brown
(Chairman)Previously served as Managing Director of Alchemy Biomedical Consulting. Is Chair of the Board at ProFactor Pharma and Babraham Institute Enterprise.